Journal of Shandong University (Health Sciences) ›› 2019, Vol. 57 ›› Issue (1): 1-5.doi: 10.6040/j.issn.1671-7554.0.2018.1067

   

Advances in focal therapy for prostate cancer

LÜ Jiaju, HU Jialin, DING Sentai   

  1. Department of Urology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, Shandong, China
  • Published:2022-09-27

PDF (PC)

22

Abstract: Focal therapy for localized prostate cancer has been proved effective and also has the potential to reduce side effects, medical burden, and the costs associated with treatments such as surgery or radiation therapy. This article reviews existing focal treatment methods, effects and research advances and looks for a tissue-preserving focal therapy, which is a minimally invasive treatment followed by most of other solid tumor treatment models.

Key words: Prostate cancer, Focal therapy, Cryotherapy, High intensity focused ultrasound, Photodynamic therapy

CLC Number: 

  • R737.3
[1] Bill-Axelson A, Holmberg L, Garmo H, et al. Radical prostatectomy or watchful waiting in early prostate cancer[J]. N Engl J Med, 2014, 370(10): 932-942.
[2] King MT, Viney R, Smith DP, et al. Survival gains needed to offset persistent adverse treatment effects in localised prostate cancer[J]. Br J Cancer, 2012, 106(4): 638-645.
[3] Carlsson S, Drevin L, Loeb S, et al. Population-based study of long-term functional outcomes after prostate cancer treatment[J]. BJU Int, 2016, 117(6B): E36-E45.
[4] Guillaumier S, Peters M, Arya M, et al. A multicentre study of 5-year outcomes following focal therapy in treating clinically significant nonmetastatic prostate cancer[J]. Eur Urol, 2018, 74(4): 422-429.
[5] Ahmed HU, Berge V, Bottomley D, et al. Can we deliver randomized trials of focal therapy in prostate cancer?[J]. Nat Rev Clin Oncol, 2014, 11(8): 482-491.
[6] Ahmed HU, Emberton M. Active surveillance and radical therapy in prostate cancer: can focal therapy offer the middle way?[J]. World J Urol, 2008, 26(5): 457-467.
[7] Calio B, Kasson M, Sugano D, et al. Multiparametric MRI: an opportunity for focal therapy of prostate cancer[J]. Semin Roentgenol, 2018, 53(3): 227-233.
[8] Hara R, Jo Y, Fujii T, et al. Optimal approach for prostate cancer detection as initial biopsy: prospective randomized study comparing transperineal versus transrectal systematic 12-core biopsy[J]. Urology, 2008, 71(2): 191-195.
[9] Ahmed HU, Moore C, Emberton M. Minimally-invasive technologies in uro-oncology: the role of cryotherapy, HIFU and photodynamic therapy in whole gland and focal therapy of localised prostate cancer[J]. Surg Oncol, 2009, 18(3): 219-232.
[10] Lindner U, Lawrentschuk N, Weersink RA, et al. Focal laser ablation for prostate cancer followed by radical prostatectomy: validation of focal therapy and imaging accuracy[J]. Eur Urol, 2010, 57(6): 1111-1114.
[11] Moore CM, Pendse D, Emberton M. Photodynamic therapy for prostate cancer-a review of current status and future promise[J]. Nat Clin Pract Urol, 2009, 6(1): 18-30.
[12] You Y, Liang X, Yin T, et al. Porphyrin-grafted lipid microbubbles for the enhanced efficacy of photodynamic therapy in prostate cancer through ultrasound-controlled accumulation[J]. Theranostics, 2018, 8(6): 1665-1677.
[13] Chen Y, Xu S, Squires A, et al. MRI-guided robotically assisted focal laser ablation of the prostate using canine cadavers[J]. IEEE Trans Biomed Eng, 2018, 65(7): 1434-1442.
[14] He MH, Chen L, Zheng T, et al. Potential applications of nanotechnology in urological cancer[J]. Front Pharmacol, 2018, 9: 745. doi:10.3389/fphar.2018.00745
[15] Jung JH, Risk MC, Goldfarb R, et al. Primary cryotherapy for localised or locally advanced prostate cancer[J]. BJU Int, 2018, doi:10.1111/bju.14519.
[16] Grampsas SA, Miller GJ, Crawford ED, et al. Salvage radical prostatectomy after failed transperineal cryotherapy: histologic findings from prostate whole-mount specimens correlated with intraoperative transrectal ultrasound images[J]. Urology, 1995, 45(6): 936-941.
[17] 郭宏骞,林廷升,连惠波,等.局限性前列腺癌冷冻治疗及其进展[J].现代泌尿外科杂志, 2014, 19(8): 499-501. GUO Hongqian, LIN Tingsheng, LIAN Huibo, et al. Advances of cryotherapy for localized prostate cancer[J]. Journal of Modern Urology, 2014, 19(8): 499-501.
[18] Ward JF, Jones JS. Focal cryotherapy for localized prostate cancer: a report from the national Cryo On-Line Database(COLD)Registry[J]. BJU Int, 2012, 109(11): 1648-1654.
[19] Bahn D, de Castro Abreu AL, Gill IS, et al. Focal cryotherapy for clinically unilateral low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years[J]. Eur Urol, 2012, 62(1): 55-63.
[20] Hill CR, ter Haar GR. Review article: high intensity focused ultrasound-potential for cancer treatment[J] Br J Radiol, 1995, 68(816): 1296-1303.
[21] Golan R, Bernstein AN, McClure TD, et al. Partial gland treatment of prostate cancer using high-intensity focused ultrasound in the primary and salvage settings: a systematic review[J]. J Urol, 2017, 198(5): 1000-1009.
[22] Ahmed HU, Hindley RG, Dickinson L, et al. Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study[J]. Lancet Oncol, 2012, 13(6): 622-632.
[23] Ahmed HU, Zacharakis E, Dudderidge T, et al. High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series[J]. Br J Cancer, 2009, 101(1): 19-26.
[24] El Fegoun AB, Barret E, Prapotnich D, et al. Focal therapy with high-intensity focused ultrasound for prostate cancer in the elderly. A feasibility study with 10 years follow-up[J]. Int Braz J Urol, 2011, 37(2): 213-219.
[25] Muto S, Yoshii T, Saito K, et al. Focal therapy with high-intensity-focused ultrasound in the treatment of localized prostate cancer[J]. Jpn J Clin Oncol, 2008, 38(3): 192-199.
[26] Stone L. Prostate cancer: light, camera, action-photodynamic therapy for low-risk disease[J]. Nat Rev Urol, 2017, 14(3): 134. doi:10.1038/nrurol.2017.1
[27] Azzouzi AR, Barret E, Moore CM, et al. TOOKAD(®)Soluble vascular-targeted photodynamic(VTP)therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer[J]. BJU Int, 2013, 112(6): 766-774.
[28] Azzouzi AR, Vincendeau S, Barret E, et al. Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer(CLIN1001 PCM301): an open-label, phase3, randomised controlled trial.[J]. Lancet Oncol, 2017, 18(2): 181-191.
[29] Lebdai S, Bigot P, Leroux PA, et al. Vascular targeted photodynamic therapy with padeliporfin for low risk prostate cancer treatment: midterm oncologic outcomes[J]. J Urol, 2017, 198(2): 335-344.
[30] Lindner U, Weersink RA, Haider MA, et al. Image guided photothermal focal therapy for localized prostate cancer: phase I trial[J]. J Urol, 2009, 182(4): 1371-1377.
[31] Oto A, Sethi I, Karczmar G, et al. MR imaging-guided focal laser ablation for prostate cancer: phase I trial[J]. Radiology, 2013, 267(3): 932-940.
[32] Valerio M, Dickinson L, Ali A, et al. Nanoknife electroporation ablation trial: a prospective development study investigating focal irreversible electroporation for localized prostate cancer[J]. J Urol, 2017, 197(3 Pt 1): 647-654.
[33] Scheltema MJ, van den Bos W, Siriwardana AR, et al. Feasibility and safety of focal irreversible electroporation as salvage treatment for localized radio-recurrent prostate cancer[J]. BJU Int, 2017. doi: 10.1111/bju.13991
[34] Feutren T, Herrera FG. Prostate irradiation with focal dose escalation to the intraprostatic dominant nodule: a systematic review[J]. Prostate Int, 2018, 6(3):75-87.
[1] AILI Aixingzi,Zhengyu GUO,Xiaofei ZHANG. Latest research advances of high intensity focused ultrasound treatment for adenomyosis [J]. Journal of Shandong University (Health Sciences), 2022, 60(7): 36-42.
[2] SUN Haoyu, JIANG Xin, CHEN Shouzhen, QU Sifeng, SHI Benkang. Multiparametric magnetic resonance imaging combined with prostate health index in the diagnosis of prostate cancer in 142 patients within PSA grey zone [J]. Journal of Shandong University (Health Sciences), 2022, 60(6): 46-50.
[3] XU Zhen, DIAO Tongxiang, ZANG Zhenjie, SHAO Dingchang, ZHANG Qi, SUN Dingqi, FU Qiang. Value of isoform［-2］proprostate-specific antigen and its derivatives in the diagnosis of prostate cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(6): 51-56.
[4] Benkang SHI,Shouzhen CHEN,Sifeng QU,Yong WANG,Lei LIU. Research progress and clinical characteristics of clinical rapidly progressing prostate cancer [J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 110-116.
[5] XU Bing, LI Yong, LIU Ming, LIU Yonghui. Silencing PRRX1 gene expression enhances the sensitivity of prostate cancer resistant cell line PC-3/DTX to docetaxel [J]. Journal of Shandong University (Health Sciences), 2021, 59(6): 103-110.
[6] SUN Dingqi, FU Qiang, ZHANG Hui, LIU Shuai, DIAO Tongxiang, CAO Qingwei, ZHANG Keqin. Clinical value of targeted multiparameter MRI and transrectal ultrasonography fusion prostate biopsy for the detection of PI-RADS≥3 prostate cancer [J]. Journal of Shandong University (Health Sciences), 2021, 59(4): 108-113.
[7] MAO Shaowei, LU Guoliang, LI Liang, XIA Qinghua. Valproic acid augments the anti-tumor potential of metformin in PC-3 cells [J]. Journal of Shandong University (Health Sciences), 2018, 56(3): 48-53.
[8] DONG Wei, XING Naidong, LÜ Jiaju, LIU Shuai, SUN Liang, CAO Qingwei, DONG Yuhao, LIU Zhao, DING Sentai. The therapeutic efficacy of a potent KSP inhibitor S(MeO)TLC against docetaxel-resistant prostate cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(9): 23-30.
[9] ZHANG Mingming, AN Yonghui, HAN Caili, ZHANG Yingqi, MA Ming, LI Na, ZOU Changpeng. Clinical efficacy of combined cellular immunotherapy and photodynamic therapy for advanced esophageal cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(1): 38-41.
[10] ZHAI Hongyun, ZHANG Denglu, WANG Guangjie, KONG Feng, CHENG Guanghui, ZHAO Shengtian. Effects of factors secreted by mouse embryonic stem cells on prostate cancer cells in vitro [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(9): 8-12.
[11] WANG Jie, ZHANG Youzhong, FENG Jinbo, LIU Hongli, ZONG Liju. Inhibitive effects of lenti virus-mediated hTERT RNA interference and TMPyP4-PDT on cervix cancer SiHa cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(1): 27-33.
[12] ZONG Liju, ZHANG Youzhong, WANG Jie, WU Shuxia, LIU Hongli, ZHANG Lu. Effects of TMPyP4-PDT on human immortal cervical epithelial H8 cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(1): 21-26.
[13] ZHANG Hong-mei1,2, WANG Hong2, CHEN Hong-li2, LI Ying-xin2, XU Ying-jun1, GUAN Wei-jun1, GU Li-chao3, CHEN Nai-yao3. Study on the photodynamic effect of PSD-007 on human breast neoplasm cell line MCF-7 [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(2): 52-57.
[14] LIU Yuanyuan, WANG Yifei, ZHANG Chunmin, LIU Yao, WEI Guo, ZHANG Chunhong, LIU Ying. Effects of ALA-PDT on Caspase-3 and Caspase-7 expressions in cutaneous squamous cell carcinoma A431 cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(12): 50-53.
[15] SHI Xiaowu, ZHAO Su. Clinical research of cryotherapy and balloon dilation for severe benign central airway stenosis through laryngeal mask [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(11): 68-72.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd